LAVA Therapeutics (LVTX)
(Delayed Data from NSDQ)
$1.79 USD
-0.12 (-6.28%)
Updated Jul 11, 2024 04:00 PM ET
After-Market: $1.78 -0.01 (-0.56%) 6:24 PM ET
2-Buy of 5 2
C Value F Growth A Momentum D VGM
Brokerage Reports
0 items in cart
LAVA Therapeutics N.V. [LVTX]
Reports for Purchase
Showing records 1 - 10 ( 10 total )
Company: LAVA Therapeutics N.V.
Industry: Medical - Biomedical and Genetics
Company: LAVA Therapeutics N.V.
Industry: Medical - Biomedical and Genetics
Company: LAVA Therapeutics N.V.
Industry: Medical - Biomedical and Genetics
Strategic Reprioritization of Clinical Pipeline; Lower PT to $6; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: HE A
Company: LAVA Therapeutics N.V.
Industry: Medical - Biomedical and Genetics
Another Big-Pharma Vote of Confidence; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: HE A
Company: LAVA Therapeutics N.V.
Industry: Medical - Biomedical and Genetics
Company: LAVA Therapeutics N.V.
Industry: Medical - Biomedical and Genetics
Unwarranted Sell-Off on LAVA-1207 Update; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: HE A
Company: LAVA Therapeutics N.V.
Industry: Medical - Biomedical and Genetics
Early Sign of LAVA-051?s Feasibility for Subcutaneous Administration; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: HE A
Company: LAVA Therapeutics N.V.
Industry: Medical - Biomedical and Genetics
Catalytic Clinical Updates Imminent; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: HE A
Company: LAVA Therapeutics N.V.
Industry: Medical - Biomedical and Genetics
SITC Data Shed More Light on Gammabody?s PD Assessment; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: HE A
Company: LAVA Therapeutics N.V.
Industry: Medical - Biomedical and Genetics
A Pioneer in ?a T Cell Engagers; Initiate With Buy and a $9 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: HE A
|